Skip to main content
Top
Published in: Abdominal Radiology 6/2021

01-06-2021 | Ovarian Cancer | Special Section: Ovarian Cancer

Assessing CT imaging features combined with CEA and CA125 levels to identify endometriosis-associated ovarian cancer

Authors: Miaomiao Li, Jing Tan, Ya Zhang, Conghui Ai, Hongbo Wang, Huimei Zhang, Yan Jin, Yizhou Chen

Published in: Abdominal Radiology | Issue 6/2021

Login to get access

Abstract

Purpose

To improve the diagnosis and identification of ovarian clear cell carcinoma (CCC) and ovarian endometrioid carcinoma (EC), we evaluated CT imaging findings and cut-off values for CEA and CA125.

Methods

The CT features and tumour markers (tumour size, location, morphology, composition, number of cysts, growth pattern of the mural nodules, mural nodule HWR, enhancement of the mural nodules, ascites, complications, CEA level, CA125 level) of 55 tumours in 52 patients with CCC, confirmed by surgery and pathology at the Yunnan Cancer Hospital from January 1, 2012 to December 30, 2018, were compared with those of 41 tumours in 36 patients with EC. All patients had a long history of endometriosis. Statistical analysis was performed using t test, chi-square test, Mann–Whitney U test, univariate analysis, multivariate logistic regression analysis and receiver-operating characteristic (ROC) curves.

Results

CCC and EC presented as large oval or irregular mixed cystic-solid masses in the pelvic region, with moderately delayed enhancement of the solid components. There was a statistically significant difference between the number of cysts, the growth pattern of the mural nodules, the presence/absence of ascites, and the levels of CEA and CA125 (P < 0.05). Most CCCs had unilocular cysts, mural nodules that were polypoid structures, and no ascites (46/55, 33/55, 42/55); most ECs had multilocular cysts and broad-based nodular structures and were ascites positive (28/41, 31/41, 21/41). The CEA positive rate was lower in the CCC group than in the EC group (2/52, 3.8% versus 11/36, 30.6%, P < 0.05), and the CA125 positive rate was high in both the CCC and EC groups (44/52, 84.6% versus EC = 35/36, 97.2%, P = 0.118). The ROC curves revealed that when the values of CEA and CA125 were higher than the cut-off values (CEA = 3.270 µg/L, CA125 = 589.400 kU/L), the diagnostic efficiency of CEA was 0.723, and the diagnostic specificity of CEA was as high as 0.903.

Conclusions

The number of cysts, growth pattern of the mural nodules, presence/absence of ascites, and levels of CEA and CA125 were useful factors for distinguishing CCC from EC; the best cut-off values of CEA and CA125 for distinguishing CCC from EC were 3.270 and 589.40, respectively. These findings may be helpful for correctly diagnosing and identifying CCC and EC.
Literature
1.
go back to reference Wilbur, M., et al., Cancer Implications for Patients with Endometriosis. Seminars in Reproductive Medicine, 2017. 35(01): p. 110-116. Wilbur, M., et al., Cancer Implications for Patients with Endometriosis. Seminars in Reproductive Medicine, 2017. 35(01): p. 110-116.
2.
go back to reference Kobayashi, H., Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol, 2009. 14(5): p. 378-82. Kobayashi, H., Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol, 2009. 14(5): p. 378-82.
3.
go back to reference Robinson, K.A., et al., Understanding malignant transformation of endometriosis: imaging features with pathologic correlation. Abdominal Radiology, 2019. Robinson, K.A., et al., Understanding malignant transformation of endometriosis: imaging features with pathologic correlation. Abdominal Radiology, 2019.
4.
go back to reference Armstrong, D.K., et al., NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw, 2019. 17(8): p. 896-909. Armstrong, D.K., et al., NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw, 2019. 17(8): p. 896-909.
5.
go back to reference Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer.
6.
go back to reference Qin, Y.Y., et al., Single and combined use of red cell distribution width, mean platelet volume, and cancer antigen 125 for differential diagnosis of ovarian cancer and benign ovarian tumors. J Ovarian Res, 2018. 11(1): p. 10. Qin, Y.Y., et al., Single and combined use of red cell distribution width, mean platelet volume, and cancer antigen 125 for differential diagnosis of ovarian cancer and benign ovarian tumors. J Ovarian Res, 2018. 11(1): p. 10.
7.
go back to reference Stiekema, A., et al., Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Gynecol Oncol, 2015. 136(3): p. 562-6. Stiekema, A., et al., Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Gynecol Oncol, 2015. 136(3): p. 562-6.
8.
go back to reference Scholler, N. and N. Urban, CA125 in ovarian cancer. Biomark Med, 2007. 1(4): p. 513-23. Scholler, N. and N. Urban, CA125 in ovarian cancer. Biomark Med, 2007. 1(4): p. 513-23.
9.
go back to reference Sturgeon, C.M., et al., National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem, 2008. 54(12): p. e11-79. Sturgeon, C.M., et al., National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem, 2008. 54(12): p. e11-79.
10.
go back to reference Bai, H., et al., The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study. Oncotarget, 2016. 7(13): p. 15566-76. Bai, H., et al., The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study. Oncotarget, 2016. 7(13): p. 15566-76.
11.
go back to reference Moro, F., et al., Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses. Ultrasound Obstet Gynecol, 2019. 53(1): p. 116-123. Moro, F., et al., Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses. Ultrasound Obstet Gynecol, 2019. 53(1): p. 116-123.
12.
go back to reference Morioka, S., et al., Magnetic resonance imaging findings for discriminating clear cell carcinoma and endometrioid carcinoma of the ovary. Journal of Ovarian Research, 2019. 12(1). Morioka, S., et al., Magnetic resonance imaging findings for discriminating clear cell carcinoma and endometrioid carcinoma of the ovary. Journal of Ovarian Research, 2019. 12(1).
13.
go back to reference Joo, H.L., et al., Preoperative discrimination of tumour stage in clear cell carcinoma of the ovary using computed tomography and magnetic resonance imaging. European Journal of Radiology, 2018. 109: p. 19-26. Joo, H.L., et al., Preoperative discrimination of tumour stage in clear cell carcinoma of the ovary using computed tomography and magnetic resonance imaging. European Journal of Radiology, 2018. 109: p. 19-26.
14.
go back to reference Ma, F., et al., Magnetic resonance imaging for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma. Journal of Ovarian Research, 2016. 9(1). Ma, F., et al., Magnetic resonance imaging for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma. Journal of Ovarian Research, 2016. 9(1).
15.
go back to reference Stern, R.C., et al., Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol, 2001. 20(2): p. 133-9. Stern, R.C., et al., Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol, 2001. 20(2): p. 133-9.
16.
go back to reference Choi, J.H., et al., Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas. Obstetrics & Gynecology Science, 2018. 61(3): p. 344. Choi, J.H., et al., Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas. Obstetrics & Gynecology Science, 2018. 61(3): p. 344.
17.
go back to reference Zhang, L., Y. Chen and K. Wang, Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer, 2019. 43(2): p. 135-144. Zhang, L., Y. Chen and K. Wang, Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer, 2019. 43(2): p. 135-144.
18.
go back to reference Ñiguez Sevilla, I., et al., Prognostic importance of atypical endometriosis with architectural hyperplasia versus cytologic atypia in endometriosis-associated ovarian cancer. Journal of Gynecologic Oncology, 2019. 30(4). Ñiguez Sevilla, I., et al., Prognostic importance of atypical endometriosis with architectural hyperplasia versus cytologic atypia in endometriosis-associated ovarian cancer. Journal of Gynecologic Oncology, 2019. 30(4).
19.
go back to reference Ye, S., et al., Comparative study of ovarian clear cell carcinoma with and without endometriosis in People’s Republic of China. Fertility and Sterility, 2014. 102(6): p. 1656-1662. Ye, S., et al., Comparative study of ovarian clear cell carcinoma with and without endometriosis in People’s Republic of China. Fertility and Sterility, 2014. 102(6): p. 1656-1662.
20.
go back to reference Sorensen, S.S. and B.J. Mosgaard, Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull, 2011. 58(11): p. A4331. Sorensen, S.S. and B.J. Mosgaard, Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull, 2011. 58(11): p. A4331.
21.
go back to reference Manabe, T., et al., Magnetic resonance imaging of endometrial cancer and clear cell cancer. Journal of computer assisted tomography, 2007. 31(2): p. 229-235. Manabe, T., et al., Magnetic resonance imaging of endometrial cancer and clear cell cancer. Journal of computer assisted tomography, 2007. 31(2): p. 229-235.
22.
go back to reference Ma, F., et al., Magnetic resonance imaging for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma. Journal of ovarian research, 2016. 9(1): p. 40. Ma, F., et al., Magnetic resonance imaging for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma. Journal of ovarian research, 2016. 9(1): p. 40.
23.
go back to reference Pozzati, F., et al., Imaging in gynecological disease (14): clinical and ultrasound characteristics of ovarian clear cell carcinoma. Ultrasound in Obstetrics & Gynecology, 2018. 52(6): p. 792-800. Pozzati, F., et al., Imaging in gynecological disease (14): clinical and ultrasound characteristics of ovarian clear cell carcinoma. Ultrasound in Obstetrics & Gynecology, 2018. 52(6): p. 792-800.
24.
go back to reference Tanase, Y., et al., Factors that Differentiate between Endometriosis-associated Ovarian Cancer and Benign Ovarian Endometriosis with Mural Nodules. Magn Reson Med Sci, 2018. 17(3): p. 231-237. Tanase, Y., et al., Factors that Differentiate between Endometriosis-associated Ovarian Cancer and Benign Ovarian Endometriosis with Mural Nodules. Magn Reson Med Sci, 2018. 17(3): p. 231-237.
25.
go back to reference Barreta, A., et al., Endometriosis-Associated Ovarian Cancer: Population Characteristics and Prognosis. International Journal of Gynecologic Cancer, 2018. 28(7): p. 1251-1257. Barreta, A., et al., Endometriosis-Associated Ovarian Cancer: Population Characteristics and Prognosis. International Journal of Gynecologic Cancer, 2018. 28(7): p. 1251-1257.
Metadata
Title
Assessing CT imaging features combined with CEA and CA125 levels to identify endometriosis-associated ovarian cancer
Authors
Miaomiao Li
Jing Tan
Ya Zhang
Conghui Ai
Hongbo Wang
Huimei Zhang
Yan Jin
Yizhou Chen
Publication date
01-06-2021
Publisher
Springer US
Published in
Abdominal Radiology / Issue 6/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-020-02571-x

Other articles of this Issue 6/2021

Abdominal Radiology 6/2021 Go to the issue